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CLINICAL IMPLICATIONS OF THE MOLECULAR BIOLOGY
OF PROSTATE CANCER: REVIEW ARTICLE
IMPLICANCIAS CLÍNICAS DE LA BIOLOGÍA MOLECULAR DEL CÁNCER DE PRÓSTATA: ARTÍCULO DE REVISIÓN
María del Carmen Castro-Mujica 1,a

ABSTRACT
To understand the term genomic heterogeneity in prostate cancer, we must understand the clonal genomic
evolution of cancer, as well as knowing that it is a dynamic and evolutionary phenomenon. Knowing the
genome of prostate cancer not only allows us to have a vision over time of the genomic alterations that occur
during its diﬀerent stages, but also to learn about the mechanisms of metastasis. In addition, knowing the
hereditary component of prostate cancer allows the evaluation of patients and to be able to identify if we are
dealing with a family at risk.
Keywords: Prostatic Neoplasms; Genetic Heterogeneity; Germ-Line Mutation. (Source : MeSH - NLM)

RESUMEN
Para enteder el término de heterogeneidad genómica en cáncer de próstata debemos comprender la
evolución genómica clonal del cáncer, así como saber que es un fenómeno dinámico y evolutivo.
Conocer el genoma del cáncer de próstata no solo nos permite tener una visión en el tiempo de las
alteraciones genómicas que se producen durante sus diferentes estadíos, sino también conocer
sobre los mecanismos de la metástasis. Además, conocer el componente hereditario del cáncer de
próstata permite la evaluación de los pacientes y poder identi car si estamos frente a una familia en
riesgo.
Palabras claves: Neoplasias de la Próstata; Heterogeneidad Genética; Mutación de Línea Germinal.

INTRODUCTION
Prostate cancer is, from a molecular point of view, biologically heterogeneous due to the diversity of inter and
intratumor molecular alterations since it is part of a dynamic and evolutionary genomic process. With the
development of new molecular techniques, such as gene sequencing, microarrays, and epigenomic studies,
among others, it has been possible to molecularly characterize prostate cancer, nding diﬀerences even
between the diﬀerent stages of the disease.
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In addition to molecular alterations at the somatic level
in prostate tumor cells, there are also variants at the
germ line level, that is, they are present in all the cells of
your body from the moment of conception, giving
them a higher risk of developing prostate cancer
throughout life and at a younger age. Men who have a
family history of prostate cancer, mainly rst-degree,
are more likely to develop the disease as it could be a
hereditary syndrome.
The objective of this review article is to present
molecular alterations at the somatic level in prostate
cancer, its molecular classi cation, genomic
heterogeneity, clonal evolution, biomarkers, as well as
genetic predisposition syndromes to prostate cancer.
MOLECULAR ALTERATIONS AT THE SOMATIC LEVEL
The main molecular alterations described in prostate
cancer include the TMPRSS2–ETS gene fusion, copy

have variants in the PTEN gene and 12-41% of cases
have copy number loss (4). On the other hand, variants in
the PI3K gene have been described in three to 4% of
prostate cancer cases and its ampli cation has been
reported in four to 10% of cases. In addition, cases of
combined variants of PTEN and TP53 have been
described, which are very aggressive(4).
Tp53
The TP53 gene is a tumor suppressor that plays a very
important role in maintaining genomic stability and
preventing carcinogenesis. Approximately three to 47%
of prostate cancer cases have variants in the TP53 gene
and between two to 15% gene loss (4). Variants in the
TP53 gene have been associated with an increased risk
of disease recurrence(1).
AR
About two to18% of prostate cancer cases have variants
in the androgen receptor AR gene (androgen receptor
gene) or gene ampli cation ( ve to 52% of cases), being
very common in cases refractory to hormonal therapy(4).
Androgen receptors belong to the group of nuclear
steroid hormone receptors and act as a liganddependent transcription factor, that controls the
expression of speci c genes(1).

number variants of TP53, AR, RB1, PTEN/PIK3CA, BRCA2,
and ATM genes, among others.
TMPRSS2–ETS gene fusion
TMPRSS2 (Transmembrane protease, serine two) is an
androgen-regulated serine protease. ETS
(erythroblastosis virus E26 oncogene homolog) is one
of the largest families of transcription factors that
includes ERG and ETV1, which are fused with the
TMPRSS2 gene in approximately 50-79% of prostate
cancer cases . This fusion is due to the deletion of a
(1)

region between both genes and is associated with a
worse prognosis in localized cases (2).
PTEN/PI3K/AKT/mTOR pathway
The PTEN/PI3K/AKT signaling pathway plays a
primordial role in the regulation of cell growth and
death, while the PI3K/AKT/mTOR pathway plays a
fundamental role in tumor metastasis (3). Variants in the
PTEN and PI3K genes are mutually exclusive since the
PTEN gene is a negative regulator of the PI3K/AKT
pathway, so the loss of PTEN is associated with a worse
prognosis (1) two to 14% of prostate cancer cases
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RB
The RB protein is a product of the RB1 gene
(Retinoblastoma one gene), a tumor suppressor which
is mutated in approximately one to 4% of prostate
cancer cases, while loss of the RB1 gene has been shown
in ve to 23% (4). An alteration in the RB1 gene leads to a
failure in the function of the protein, stimulating the
release of the androgen receptor and conferring
resistance to castration (1). The RB1 gene is frequently
deleted or methylated in castration-resistant prostate
cancer(1).
APC
The APC gene is a tumor suppressor that encodes a
protein that acts antagonistically to the Wnt signaling
pathway ( 1 ) . Hypermethylation of the APC gene
promoter is a predictor of poor prognosis in prostate
cancer. Approximately three to 10% of prostate cancer
cases have variants in the APC gene (4).
MYC
The MYC proto-oncogene encodes a protein that plays
an important role in cell cycle progression, apoptosis,
and transformation(1). Activation of this proto-oncogene
transforms it into an oncogene that is expressed
through gene ampli cation, thus stimulating cancer
development, which is found in approximately two to
20% of prostate cancer cases(4).
BRCA2
BRCA2 is a tumor suppressor gene, which is responsible

2
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for maintaining genomic stability, mainly in the double-

DNA damage and to maintain genomic stability (1).

stranded DNA repair pathway by homologous

Approximately 5% of prostate cancer cases have

recombination(1). Approximately 9% of prostate cancer

somatic ATM variants, including 1% germline variants

cases present variants in BRCA2, of which two to 6% are

(5)

.

due to germline variants, which are a prognostic factor
for survival in all stages of prostate cancer, including
localized cases(5).

TMPRSS2-ETS GENE FUSION
In 2005, Scott Tomlims et al. identi ed a recurrent
rearrangement in more than half of the prostate cancer
cases analyzed, which led to the gene fusion of the

When the variants are germinal, the relatives of the

TMPRSS2 gene (21q22) with members of the ETS

patient have a greater probability of having inherited

transcription factor family (ERG, ETV1, and ETV4 located

the mutated gene, conferring risk of developing a

at loci 21q22, 7p21 and 17q21, respectively) (6-8).

neoplasm related to hereditary breast and ovarian
cancer syndrome in carriers.

Assessing the presence of the TMPRSS2-ETS gene
fusion in prostate cancer samples serves as a prognostic
marker of the disease. Determination of ERG

ATM

overexpression by immunohistochemistry has been

ATM is a DNA repair gene that acts at the cell cycle level

highly correlated with gene fusion status with 86%

as a necessary controller for the cellular response to

sensitivity and speci city (6).

La evolución genómica del cáncer de próstata desde el epitelio normal hasta metástasis y el cáncer de próstata
resistente a castración. Los estadíos patológicos del cáncer de próstata están representados en el lado izquierdo
con la correspondiente mutación genómica en el lado derecho. Tomado de “The genomic evolution of
human prostate cancer” (7).
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Progresión del cáncer de próstata. La pérdida de PTEN conlleva a la activación de AKT, la cuál actúa en junto con
la proteína quimérica TMPRSS2-ERG para promover la progresión del cáncer de próstata, desde un estadío pre-maligno
como la neoplasia prostática intraepitelial (PIN). ARE: androgen response elements; TA: transcriptional activator;
TF: transcription factor. Tomado de “TMPRSS2-ERG and PTEN loss in prostate cancer” (8).

Modelo de la secuencia de eventos genómicos en la progresión del cáncer de próstata. La adquisición de la
haploinsu ciencia de PTEN en precursores del cáncer de próstata puede ser un evento temprano en la
caracinogénesis. La disminución de los niveles de la proteína PTEN puede facilitar la inestabilidad genómica
llevando a la adquisición de rearreglos como TMPRSS2-ETS, actuando ambos de forma sinérgica en la progresión
del cáncer de próstata. La continua inestabilidad conlleva a una heterogeneidad tumoral debido a
la presencia de subclonas. La pérdida completa de la función de PTEN (homocigota) favorece a la progresión
tumoral tras activar la vía de AKT (9).

MOLECULAR CLASSIFICATION OF PROSTATE
CANCER
There is currently a molecular classi cation of primary
prostate cancer. All seven molecular subtypes of
primary prostate cancer, considered the earliest drivers
of carcinogenesis, are de ned by ERG fusions (46%),
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ETV1/ETV4/FLI1 fusions or overexpression (8%, 4%, 1%,
respectively), or by variants in the genes SPOP (11%),
FOXA1 (3%) and IDH1 (1%) (nine to 11), while 26% is
made up of other variants. Likewise, it has been
determined that the molecular pro les in primary and
metastatic prostate cancer are diﬀerent.

4

Castro-Mujica: Clinical implications of the molecular biology of prostate cancer

GENOMIC HETEROGENEITY IN PROSTATE CANCER

provide us with evidence of a clonal expansion of
prostate cancer with the diﬀerent mutational events

The heterogeneity can be intratumor and intertumor, as
well as in the diﬀerent stages of prostate cancer, which
is why we currently speak of molecular subtypes in
prostate cancer. The high tumor heterogeneity has
implications for the diagnosis, follow-up, and treatment
of patients with prostate cancer (12).
Molecular studies such as next-generation gene
sequencing, as well as studies of circulating tumor cells,
epigenetic studies, and microarrays, among others,

that occur in its genome. The somatic level at various
stages of disease progression. There are investigations
of the genomic composition of multiple sites of
metastasis in the same patient or have followed the
clonal evolution longitudinally in the tissues. To
understand the origin of prostate cancer, its behavior
over time, and the risks of disease progression, it is
necessary to know the spatial and temporal genomic
evolution of prostate cancer.

Terapia blanco basada en las vías moleculares alteradas en cáncer de próstata. Tomado de “Genomic Proﬁling
Deﬁnes Subtypes of Prostate Cancer with the Potential for Therapeutic Stratiﬁcation”(12).

The clonal architecture of primary and metastatic

Studies reveal that the loss or variant of the TP53 gene,

tumors, allows us to know the clonal evolution during

as well as the loss of PTEN, occur before or at the

the progression of the disease . Various variants, as

beginning of metastasis, indicating that they are drivers

well as altered molecular pathways in both the primary

of metastatic spread

tumor and metastasis, have been identi ed, con rming

molecular subtypes already mentioned (ETS fusions,

intratumor heterogeneity and thus evidencing that

variants in FOXA1, FLI1, SPOP, and IDH1) there may be

metastasis and resistance to androgen deprivation

an acquisition of new variants that lead to metastases,

treatment occur due to diﬀerent molecular alterations

which could not be preferentially present in any of

acquired over time .

these subtypes(13).

(13)

(13)

(13)

. In addition to the seven
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Other important

ndings such as the androgen

The study of the prostate cancer genome not only

receptor (AR), which is altered in more than 60% of cases

allows us to have a vision over time of the genomic

of metastatic prostate cancer, and which is also a

alterations that occur during the diﬀerent stages of

mediator for resistance to androgen deprivation

prostate cancer but also to learn about the mechanisms

therapy (ADT), which can acquire new variants after

of metastasis. Metastatic spread can occur through

metastasis (14). What is not yet clearly known is whether

m o n o c l o n a l o r p o l yc l o n a l s e e d i n g b e t we e n

these rare subclones originated in the primary tumor or

metastases, or in waves originating from the primary

early in the metastases, possess alterations in the AR

tumor

that subsequently promote resistance to ADT, or

propagation is not only unidirectional, for example,

whether these alterations arise after metastasis and

when metastatic subclones reach the surgical bed of

initial ADT treatment .

the resected primary tumor ( gure 1 y 2).

(13)

(14)

. It has also been shown that clonal

Genes y vías moleculares alterados en diferentes estadíos del cáncer de próstata. Los factores ambientales imparten presiones
de selección sobre las poblaciones clonales para conducir a la metástasis y en última instancia a la resistencia a la
terapia de deprivación androgénica. La inactivación de TP53 y de PTEN se observan con más frecuencia
en el cáncer de próstata resistente a castración (CRPC) metastásico en comparación con el cáncer de próstata primario,
probablemente desempeñando un papel conductor de la metástasis. Los mediadores de la resistencia a la ADT se
observan luego de la diseminación metastásica. Tomado de “Clonal origin and spread of metastatic prostate cancer” (13).
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Figure 1. Clonal evolution of prostate cancer. A. A rare clone in the primary tumor (green) acquires metastatic potential and
is seeded in diﬀerent anatomical sites over time (green arrows). B. Metastatic subclones (green) that are seeded at diﬀerent
locations, including bidirectionally between metastatic sites (green arrows), can also seed the surgical bed again. C. The clonal
populations of the diﬀerent metastatic sites are planted in diﬀerent anatomical sites but in a polyclonal way, such as
metastatic subclone 1 (green) is planted in the left rib and right shoulder (green arrows), but a new subclone arises in the right
shoulder (purple) (metastatic subclone 2), and both seed the right rib. Taken from “Clonal origin and spread of metastatic
prostate cancer” (13).

Figure 2. A rare clone in the primary tumor (blue) acquires metastatic potential (metastatic subclone 1) and is seeded
elsewhere (blue arrow), where subclonal populations acquire new variants. Following androgen deprivation therapy (+ADT),
a subclonal population (yellow) that possesses variants resistant to this treatment (ADT-resistant subclone 1) undergoes
clonal expansion and spreads (yellow arrows) to a distant site. The acquisition of new variants can generate a new population
of subclones resistant to ADT 2 (grey). The seed mix of clones resistant to therapy seed other sites in a polyclonal fashion, even
bidirectionally (yellow and gray arrows). Taken from “Clonal origin and spread of metastatic prostate cancer” (13).
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There is evidence that after radical prostatectomy,

Prostate cancer or iginates through a clonal

tumor samples have multiple intraprostatic cancer foci

evolutionary process, due to a sequential accumulation

that are separate and may be biologically variable in

of variants to the point where these variants promote

their potential for aggressiveness and disease

the development of a neoplastic phenotype (these

progression (15). Heterogeneity can be of two types,
intratumor (diﬀerent molecular alterations in multiple
cancer foci in the tumor specimen from the same
patient) and intertumor (such as diﬀerent molecular
alterations in patients with the same Gleason score) (15).
Through next-generation gene sequencing, it has been

variants are called "drivers") (16) , diﬀers in its molecular
composition at each stage of the disease. Some of these
driver variants accelerate the acquisition of new
variants by hindering the activity of some cellular
mechanisms to detect or repair DNA damage or to

possible to identify a variety of molecular alterations in

respond with programmed cell death. The increase in

prostate cancer such as gene fusions, ampli cations,

the rate of variants leads to the acquisition of variants

hemizygous and homozygous deletions, and/or point

that have no immediate functional relevance for the cell

variants, which shows that there is genomic

(passenger variants) but that will later become relevant

heterogeneity.

or even vulnerable as therapeutic targets

.

(17-19)

Modelos monoclonales y policlonales de metástasis de un cáncer de próstata primario multifocal. (a) En el modelo monoclonal,
todas las lesiones metastásicas derivan de una célula antecesora en uno de los focos del cáncer de próstata primario multifocal.
(b) En el modelo policlonal, múltiples focos genómicamente distintos en el cáncer primario de próstata pueden, independiente,
progresar y hacer metástasis portando múltiples alteraciones clonales distintas a las originadas en el tumor primario. En ambos
modelos, la adquisición subsecuente de mutaciones (azul y rojo oscuro) conlleva a una diversidad genómica. Tomado de
”Intrapatient heterogeneity in prostate cancer” (18).
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Trayectoria de la evolución del cáncer: lineal y rami cado. (a) Evolución lineal con extensiones clonales sucesivas, eliminando cada
clon anterior. (b) Evolución lineal con extensiones clonales incompletas, donde se observa que en los puntos de tiempo T=2 y T=3
habría una heterogeneidad subclonal. (c) Evolución rami cada, donde surgen clonas hermanas de forma independiente y se
expanden en paralelo creando una extensa heterogeneidad subclonal. En este tipo de evolución, las clonas hermanas compiten
incluso por recursos como nutrientes y oxígenos, además de competir por el espacio (ambiente tumoral). (d) Pueden existir
extensiones clonales en la evolución rami cada, lo que conlleva a la extinción de las ramas del árbol evolutivo que no eran
ancestrales al clon recién dominante. Tomado de “The evolution of the unstable cancer genome” (19).

Tomado de “New Strategies in Prostate Cancer: Translating Genomics into the Clinic”(17).
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To perform precision medicine in patients with prostate

patients with elevated PSA and negative biopsies,

cancer, it is necessary that, at the time of diagnosis

which could help reduce the number of unnecessary

through biopsy, molecular analysis is requested to

biopsies (23).

detect conductive variants in the tumor, and based on
its molecular pro le, determine monitoring and

In addition to being a common rearrangement in

treatment. Subsequently, if the disease progresses or if

prostate cancer, the TMPRSS2-ERG gene fusion serves

there is resistance to treatment, it is also necessary to

as a molecular biomarker in prostate cancer with a

carry out a molecular analysis, because the molecular

speci city of 90% and a positive predictive value of 94%
(24)

pro le is variable in each stage of the disease.
BIOMARKERS IN PROSTATE CANCER
Biomarkers are widely used for screening, detection,
and prognosis of prostate cancer, revolutionizing the
diagnosis and monitoring of the disease. Despite
various studies on prostate cancer, there is no molecular

. With the detection of this gene fusion, the

probability of nding cancer in the biopsy increases
from 15% to 90%, and even if the gene fusion is
detected in urine and the biopsy does not detect
cancer, it is necessary to repeat the biopsy, due to the
high speci city of this biomarker (24). In addition, this
gene fusion is associated with a poor prognosis in
patients who carry it in the tumor(23). The combination of

biomarker with a potential clinical application for

detection of TMPRSS2-ERG and PCA3 in urine improves

diagnosis and strati cation in all stages of the disease,

the performance of PSA alone for prostate cancer

from localized to metastatic. Prostate-speci c antigen
(PSA) is usually used routinely as a marker, however, it

detection and clinically meaningful cancer prediction
.

(25)

has a low positive predictive value in localized prostate
cancer and does not diﬀerentiate the stage of the
disease (20-21).

Genetic alterations at the germinal level are molecular
biomarkers, that allow the calculation of risk in patients
with prostate cancer because it has been shown to

PCA3 (9q21–22) is a highly expressed non-coding

in uence the aggressiveness of prostate cancer and

mRNA in prostate tumors, which can be detected in

patient survival (23). In addition, the presence of variants

urine and prostate uid in patients with prostate cancer,

in some of these genes is associated with the earlier

in addition to being approved by the FDA and being

presentation of cancer as well as a family history of

available in various laboratories in the world. The cut-oﬀ

prostate cancer.

point approved by the FDA is 25 since it is at this point
that there is a balance between the sensitivity and
speci city of the test (22). Several studies also use the cutoﬀ point 35 (22). A PCA3 value > 35 in urine has a
sensitivity of 66% and speci city of 76% for the
diagnosis of prostate cancer compared to PSA in serum
(speci city 47% and sensitivity 65%) (23). The study of
PCA3 in urine obtained after the prostate massage is
superior to serum PSA in predicting the result of the
biopsy with a sensitivity and speci city of 70% and 80%

Other promising biomarkers in prostate cancer are
changes in DNA methylation, histone acetylation, or
microRNAs, which can lead to gene silencing, resulting
in altered gene expression without altering the DNA
sequence (23). Hypermethylation of the glutathione Stransferase P1 (GSTP1) gene is one of the most
prevalent (90%) and can be detected in both serum and
urine of patients; however, it is not speci c for prostate
cancer since it has been seen in approximately 70% of
cases of high-grade intraepithelial neoplasia(23).

respectively, it also has a negative predictive value of
90%

. The urine test can predict the presence of

(22)

EPIGENETIC ALTERATIONS AND METHYLATION

prostate cancer in a biopsy, with PCA3 levels being

STUDIES IN PROSTATE CANCER

independent of prostate volume and serum PSA (23).

Changes in DNA methylation together with epigenetic

Elevated levels of PCA3 have even been shown in

silencing of some genes are the earliest somatic
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changes identi ed in the development of prostate
cancer (26). The GSTP1 gene encodes an enzyme
responsible for protecting the cell from genome
damage(6). The loss of GSTP1 expression is an early event
in the onset of carcinogenesis since GSTP1 gene
methylation has been shown in ve to 10% of cases of

in ammatory proliferative atrophy and in more than
70% of prostatic intraepithelial neoplasia. high grade (6).
GSTP1 promoter methylation is associated with a risk of
recurrence in patients with prostate cancer, which
makes it a marker of recurrence (6).

Poblaciones celulares subclonales di eren en sus per les genómicos y epigenómicos a nivel intratumoral mostrando la
heterogeneidad en un mismo caso (casos del 1-5 de izquierda a derecha). (A) Tipo de tejido por cada caso está de nido por colores:
verde: tejido normal; naranja: lesión pre-maligna PIN; azul: tumor primario; rojo: metástasis ganglionar LNM. El nivel de metilación se
presenta en rango, donde el color azul representa un bajo nivel de metilación y el color amarillo representa el mayor nivel de
metilación (de 0% a 100%). (B) Alteraciones en el número de copias en diferentes regiones de un mismo tumor, donde las deleciones
se representan en color azul y las ampli caciones en color rojo, las cuales se presentan de acuerdo a los cromosomas del 1 al X.
Tomado de “Intratumor DNA Methylation Heterogeneity Reﬂects Clonal Evolution in Aggressive Prostate Cancer”(26).

CIRCULATING TUMOR CELLS IN PROSTATE
CANCER
Among the new molecular biomarkers used in prostate
cancer is the detection of circulating tumor cells (CTCs)
in peripheral blood, and it is used as a prognostic tool
since it has been proposed that the spread of CTCs in

ml of venous blood has been signi cantly determined
as a prognostic marker for overall survival(21).

GENETIC PREDISPOSITION TO PROSTATE
CANCER
Prostate cancer has a hereditary component,
which is characterized by the presence of cancer at

the blood is an essential mechanism of metastasis (21).

an early age, having a family history of prostate

Screening for CTCs is FDA-approved for monitoring the

cancer and other tumors, due to germline variants

treatment of metastatic prostate cancer

in BRCA1/2 genes, MMR (MLH1, MSH2, MSH6,

(21)

. In

metastatic prostate cancer, th e CTCs threshold per 7.5

PMS2), HOXB13, among others(27).

Pág. 607

Published by INICIB-URP, 2021

11

Revista de la Facultad de Medicina Humana, Vol. 22 [2021], Iss. 3, Art. 17

Figure 3. Genes and phenotypes of genetic syndromes with a predisposition
to prostate cancer

Figure 4. Model of frequent and rare genetic variants with a diﬀerent eﬀect on the genetic
risk of developing prostate cancer. Taken from “Molecular Updates of
Prostate Cancer” (6)
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Reference criteria for genetic evaluation of patients
with prostate cancer(27) :

with a family at risk. According to the types of
neoplasms, age of presentation, and inheritance
pattern, we will be able to de ne the genetic syndrome

·Age less than or equal to 65 years.

and thus direct the molecular study to identify germinal
variants in the patient and their relatives.

·Gleason > seven and family history of neoplasms
related to Hereditary Breast Ovarian Cancer Syndrome.
·Family history of any cancer related to Hereditary
Breast Ovarian Cancer Syndrome, hereditary prostate
cancer, or Lynch syndrome, mainly in a rst or seconddegree relative.

The HOXB13 gene has been identi ed as a prostate
cancer susceptibility gene (28). Germline variants in the
HOXB13 gene have been associated with a two to eightfold increase in risk, these cases being those
corresponding to hereditary prostate cancer

. A

(27)

germline variant in HOXB13, which is recurrent, G84E,
For the evaluation of patients with a suspected genetic
predisposition to prostate cancer, it is necessary to carry
out a family tree, to be able to identify if we are dealing

p.(Gly84Glu), c.251G>A, has been frequently reported
in patients diagnosed with prostate cancer at an early
age (2.2%) and family history (3.1%) (28).

Figure 5. Structure of the HOXB13 gene and the distribution of pathogenic variants identi

ed by gene
sequencing reported in patients with prostate cancer. Taken from “Identi cation of Two
Novel HOXB13 Germline Mutations in Portuguese Prostate Cancer Patients” (28)

Figure 6. Sanger sequencing electropherogram showing the variant HOXB13 c.383C>A, p.(Ala128Asp)
in heterozygosity at the germinal level. Taken from “Identi cation of Two Novel
HOXB13 Germline Mutations in Portuguese Prostate Cancer Patients” (28)
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Germline variants in the BRCA1 and BRCA2 genes

disease (29). Likewise, germline variants in the BRCA2

correspond to cases of Hereditary Ovarian Breast

gene confer a 7.3-8.6 times greater risk of developing

Cancer Syndrome, where in addition to the risk of breast
cancer, ovarian cancer, melanoma, and pancreas, there
is a risk in men to develop prostate cancer (27).

prostate cancer before the age of 65, compared to nonvariant carriers (28). In young patients, the prevalence of
germline variants in the BRCA2 gene is 2.9%, conferring

Germline variants in the BRCA2 gene have been

a 23-fold greater risk of developing prostate cancer up

associated with a more aggressive phenotype of the

to 56 years of age (28).

A la izquierda, se presenta la probabilidad de sobrevida en cáncer de próstata según si el paciente posee o no mutaciones germinales
en el gen BRCA2 (p<0.0001). A la derecha, se presenta la probabilidad de sobrevida en cáncer de próstata en pacientes portadores de
mutación en el gen BRCA2 según estadío de la enfermedad. Tomado de “The impact of a BRCA2 mutation on mortality from screendetected prostate cancer” (29).

In cases associated with Lynch syndrome, due to

In addition, germline variants have been reported in

variants in the MMR genes involved in the repair of DNA

other DNA repair genes such as ATM, CHEK2, PALB2,

replication errors, the risk of prostate cancer is three

RAD51D, and RAD51C, among others (30).

times higher compared to the general population(27).
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Figure 7. Distribution of 16 DNA repair genes identi

ed with a pathogenic variant
at the germinal level. Taken from “Inherited DNA-Repair Gene Mutations in Men
with Metastatic Prostate Cancer” (30)

Figure 8. Family tree of a family with hereditary prostate cancer. The proband (arrow) and
two relatives ( rst and second degree) have a diagnosis of prostate cancer.
Taken from “How I Do It: Genetic counseling and genetic testing for
inherited prostate cancer” (27)
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Figure 9. Family tree of a family with Hereditary Breast Ovarian Cancer Syndrome. The proband
(arrow) with prostate cancer and two rst-degree relatives (father and sister) were diagnosed
with prostate cancer and breast cancer, respectively. He also has two second-degree relatives
(paternal aunts) with ovarian cancer. Taken from “How I Do It: Genetic counseling and genetic
testing for inherited prostate cancer” (27)

Figure 10. .

Family tree of a family with Lynch syndrome. The proband (arrow) with prostate
cancer and rst and second relatives with neoplasms related to Lynch syndrome (colon,
endometrial, and prostate cancer). Taken from “How I Do It: Genetic counseling
and genetic testing for inherited prostate cancer” (27)
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CONCLUSION:
Knowing the molecular alterations of prostate cancer,
as well as its molecular classi cation, genomic
heterogeneity, and clonal evolution allows adequate
management of patients. In addition, the collection of
data from the patient's family history makes it possible

Authorship contributions: The author participated in
the genesis of the idea, project design, data collection
and interpretation, as well as preparation of the
manuscript for this research work.

to suspect a genetic predisposition to prostate cancer
and thus refer him for timely genetic counseling and to
be able to provide him with follow-up and therapeutic
options.
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